Could US-Style Priority Review Vouchers Drive European Neglected Disease R&D?

 
• By Francesca Bruce

Having its own priority review vouchers could serve as an important pull incentive for neglected disease R&D in Europe, although the unpredictable nature of the vouchers may deter some investors.

Monkeypox virus
Diseases traditionally found in the developing world are increasingly present in Europe thanks to factors such as climate change.

More from Europe

More from Vaccines